Current treatment of epilepsy is symptomatic, its goal is to suppress seizures, it fails in 30% of patients and it does not prevent the development of epilepsy. Our objective is to transform the treatment of epilepsy from suppression of seizures towards prevention of the development of epilepsy with focus on subjects-at-risk of epilepsy after traumatic brain injury (TBI). We will use clinically applicable biomarkers to identify subjects at risk by recording changes in sleep electrophysiology. In a given subject, we will identify epileptogenic brain area by recording oscillatory electrophysiological activity that pinpoints epileptogenic region in both animal models and human epilepsy. We will identify molecular changes in the epileptogenic region and screen drugs from compound libraries that mitigate harmful molecular changes. Finally, we will perform an experimental study to show that the treatment will mitigate epileptogenic molecular changes and epileptiform activity in brain tissue.

2022

2026